Prasugrel for Secondary Prevention of Thrombotic Stroke.
作者信息
Yagita Yoshiki
机构信息
Department of Stroke Medicine, Kawasaki Medical School.
出版信息
J Atheroscler Thromb. 2023 Mar 1;30(3):220-221. doi: 10.5551/jat.ED213. Epub 2022 Jul 29.
Abstract
摘要
相似文献
1
Prasugrel for Secondary Prevention of Thrombotic Stroke.普拉格雷用于血栓性卒中的二级预防
J Atheroscler Thromb. 2023 Mar 1;30(3):220-221. doi: 10.5551/jat.ED213. Epub 2022 Jul 29.
2
Impact of clopidogrel and potent P2Y 12 -inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: a systematic review and meta-analysis.氯吡格雷和强效 P2Y12 抑制剂对急性冠脉综合征或经皮冠状动脉介入治疗患者的死亡率和卒中的影响：系统评价和荟萃分析。
Thromb Haemost. 2013 Jan;109(1):93-101. doi: 10.1160/TH12-06-0377. Epub 2012 Nov 29.
3
Associations Between Chronic Kidney Disease and Outcomes With Use of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Report From the PROMETHEUS Study.慢性肾脏病与经皮冠状动脉介入治疗的急性冠状动脉综合征患者使用普拉格雷与氯吡格雷治疗结局的相关性：来自 PROMETHEUS 研究的报告。
JACC Cardiovasc Interv. 2017 Oct 23;10(20):2017-2025. doi: 10.1016/j.jcin.2017.02.047. Epub 2017 Aug 2.
4
Secondary prevention of acute coronary events with antiplatelet agents (SPACE-AA): One-year real-world effectiveness and safety cohort study in the French nationwide claims database.抗血小板药物二级预防急性冠脉事件（SPACE-AA）：法国全国索赔数据库中的一年真实世界有效性和安全性队列研究。
Atherosclerosis. 2019 Feb;281:98-106. doi: 10.1016/j.atherosclerosis.2018.11.037. Epub 2018 Dec 7.
5
Real-world observations with prasugrel compared to clopidogrel in acute coronary syndrome patients treated with percutaneous coronary intervention in the United States.在美国接受经皮冠状动脉介入治疗的急性冠脉综合征患者中，普拉格雷与氯吡格雷的真实世界观察比较。
Curr Med Res Opin. 2014 Nov;30(11):2207-16. doi: 10.1185/03007995.2014.941055. Epub 2014 Jul 18.
6
VERifyNow in DIabetes high-on-treatment platelet reactivity: a pharmacodynamic study on switching from clopidogrel to prasugrel.糖尿病高治疗状态下血小板反应性的即时检验：从氯吡格雷转换为普拉格雷的药效学研究
Acta Cardiol. 2015 Dec;70(6):728-34. doi: 10.2143/AC.70.6.3120187.
7
Switching from Clopidogrel to Prasugrel in patients undergoing PCI: A meta-analytic overview.经皮冠状动脉介入治疗（PCI）患者中从氯吡格雷转换为普拉格雷：一项荟萃分析概述。
Platelets. 2016;27(2):93-104. doi: 10.3109/09537104.2015.1042447. Epub 2015 May 13.
8
Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial.来自TRITON-TIMI 38试验的急性冠状动脉综合征患者中，与氯吡格雷相比，普拉格雷可降低心血管事件复发率。
Eur Heart J. 2008 Oct;29(20):2473-9. doi: 10.1093/eurheartj/ehn362. Epub 2008 Aug 5.
9
Comparison of prasugrel and clopidogrel-treated patients with acute coronary syndrome undergoing percutaneous coronary intervention: A propensity score-matched analysis of the Acute Myocardial Infarction in Switzerland (AMIS)-Plus Registry.接受经皮冠状动脉介入治疗的普拉格雷与氯吡格雷治疗急性冠状动脉综合征患者的比较：瑞士急性心肌梗死（AMIS）-Plus注册研究的倾向评分匹配分析。
Eur Heart J Acute Cardiovasc Care. 2016 Feb;5(1):13-22. doi: 10.1177/2048872614566946. Epub 2015 Jan 22.
10
Efficacy of ex vivo autologous and in vivo platelet transfusion in the reversal of P2Y12 inhibition by clopidogrel, prasugrel, and ticagrelor: the APTITUDE study.体外自体和体内血小板输注逆转氯吡格雷、普拉格雷和替格瑞洛对P2Y12抑制作用的疗效：APTITUDE研究
Circ Cardiovasc Interv. 2015 Nov;8(11):e002786. doi: 10.1161/CIRCINTERVENTIONS.115.002786.
本文引用的文献
1
Efficacy and Safety of Prasugrel vs Clopidogrel in Thrombotic Stroke Patients With Risk Factors for Ischemic Stroke Recurrence: A Double-blind, Phase III Study (PRASTRO-III).普拉格雷与氯吡格雷治疗伴有缺血性脑卒中复发危险因素的血栓性脑卒中患者的疗效和安全性：一项双盲、III 期研究（PRASTRO-III）。
J Atheroscler Thromb. 2023 Mar 1;30(3):222-236. doi: 10.5551/jat.63473. Epub 2022 May 21.
2
Efficacy and Safety of Prasugrel by Stroke Subtype: A Sub-Analysis of the PRASTRO-I Randomized Controlled Trial.普拉格雷治疗不同类型卒中的疗效及安全性：PRASTRO-I 随机对照试验的亚组分析。
J Atheroscler Thromb. 2021 Feb 1;28(2):169-180. doi: 10.5551/jat.56093. Epub 2020 Jun 4.
3
Safety and Efficacy of Prasugrel in Elderly/Low Body Weight Japanese Patients with Ischemic Stroke: Randomized PRASTRO-II.老年/低体重日本缺血性脑卒中患者普拉格雷的安全性和有效性：随机 PRASTRO-II 研究。
Cerebrovasc Dis. 2020;49(2):152-159. doi: 10.1159/000506825. Epub 2020 Mar 24.
4
Comparison of prasugrel and clopidogrel in patients with non-cardioembolic ischaemic stroke: a phase 3, randomised, non-inferiority trial (PRASTRO-I).普拉格雷与氯吡格雷在非心源性缺血性脑卒中患者中的比较：一项 3 期、随机、非劣效性试验（PRASTRO-I）。
Lancet Neurol. 2019 Mar;18(3):238-247. doi: 10.1016/S1474-4422(18)30449-6. Epub 2019 Feb 12.
5
Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: the PRASFIT-ACS study.在日本急性冠脉综合征患者中，调整剂量的普拉格雷与氯吡格雷相比的疗效和安全性：PRASFIT-ACS研究
Circ J. 2014;78(7):1684-92. doi: 10.1253/circj.cj-13-1482. Epub 2014 Apr 22.
6
Thienopyridine derivatives versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients.噻吩并吡啶衍生物与阿司匹林用于预防高血管风险患者的中风及其他严重血管事件的比较
Cochrane Database Syst Rev. 2009 Oct 7;2009(4):CD001246. doi: 10.1002/14651858.CD001246.pub2.
7
Prasugrel versus clopidogrel in patients with acute coronary syndromes.普拉格雷与氯吡格雷用于急性冠状动脉综合征患者的比较。
N Engl J Med. 2007 Nov 15;357(20):2001-15. doi: 10.1056/NEJMoa0706482. Epub 2007 Nov 4.
8
Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects.细胞色素P450 2C19功能缺失多态性是健康受试者中氯吡格雷反应性的主要决定因素。
Blood. 2006 Oct 1;108(7):2244-7. doi: 10.1182/blood-2006-04-013052. Epub 2006 Jun 13.
9
Thienopyridines or aspirin to prevent stroke and other serious vascular events in patients at high risk of vascular disease? A systematic review of the evidence from randomized trials.噻吩并吡啶类药物或阿司匹林用于预防血管疾病高危患者的中风及其他严重血管事件？对随机试验证据的系统评价
Stroke. 2000 Jul;31(7):1779-84. doi: 10.1161/01.str.31.7.1779.
Zotero 插件